{"product_id":"international-myeloma-society-educational-workshop-2025","title":"International Myeloma Society Educational Workshop 2025","description":"\u003cdiv class=\"group-header field-group-div clearfix\"\u003e\n\u003cdiv class=\"group-header-inner field-group-div\"\u003e\n\u003cdiv class=\"group-course-header-right field-group-div\"\u003e\n\u003cdiv class=\"field field-name-title field-type-ds field-label-hidden\"\u003e\n\u003cdiv class=\"field-items\"\u003e\n\u003cdiv class=\"field-item even\"\u003e\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\n\u003cdiv class=\"featured__product__tab__content__item__header\"\u003e\n\u003cdiv class=\"fusion-layout-column fusion_builder_column fusion-builder-column-6 fusion_builder_column_3_5 3_5 fusion-flex-column\"\u003e\n\u003cdiv class=\"fusion-column-wrapper fusion-column-has-shadow fusion-flex-justify-content-flex-start fusion-content-layout-column\"\u003e\n\u003cdiv class=\"fusion-text fusion-text-2\"\u003e\n\u003cdiv class=\"cme-gallery\"\u003e\n\u003cdiv class=\"container\" data-testid=\"cme-gallery\"\u003e\n\u003cdiv class=\"grid col-span-full mt-3 lg:mt-0\"\u003e\n\u003cdiv class=\"cme-gallery__description has-rich-text col-span-full lg:col-span-9 type-body has-rich-text\"\u003e\n\u003ch1 class=\"product_title entry-title\"\u003eInternational Myeloma Society Educational Workshop 2025\u003c\/h1\u003e\n\u003cstrong\u003e+ Target Audience: hematologists, medical oncologists, nephrologists, and infectious disease specialists\u003c\/strong\u003e\n\n\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cp data-path-to-node=\"2\"\u003eThis dynamic educational workshop focuses on the diagnosis, treatment, and monitoring of plasma cell malignancies, exploring both current practices and opportunities for improvement. The program features a blend of lectures and interactive roundtable discussions centered on hot and controversial topics. It highlights point-counterpoint conversations between invited speakers and local hematologists, utilizing challenging clinical cases and questions to drive the educational experience in the evolving landscape of multiple myeloma.\u003c\/p\u003e\n\u003cp data-path-to-node=\"3\"\u003e\u003cb data-path-to-node=\"3\" data-index-in-node=\"0\"\u003eLearning Objectives\u003c\/b\u003e\u003c\/p\u003e\n\u003cp data-path-to-node=\"3\"\u003eUpon completion of this workshop, participants will be able to:\u003c\/p\u003e\n\n\u003cul data-path-to-node=\"4\"\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,0,0\"\u003eEvaluate current diagnostic testing, minimal residual disease (MRD) testing, and new risk stratification models for multiple myeloma.\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,1,0\"\u003eDetermine optimal management strategies for Smoldering Multiple Myeloma (SMM) and Newly Diagnosed Multiple Myeloma (NDMM), differentiating between transplant-eligible and non-eligible patients.\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,2,0\"\u003eDesign effective sequencing strategies for relapsed and refractory multiple myeloma (RRMM) and incorporate novel immunotherapies, including CAR T cells and bispecific T cell engagers.\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,3,0\"\u003eManage myeloma-related complications effectively, particularly bone disease, renal failure, and treatment-related infections.\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,4,0\"\u003eFormulate treatment plans for challenging clinical scenarios, such as extramedullary disease, plasma cell leukemia, patient frailty, and relapse after T cell-redirected therapies.\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"4,5,0\"\u003eAddress and manage other plasma cell disorders, specifically Waldenström’s Macroglobulinemia and AL Amyloidosis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-path-to-node=\"5\"\u003e\u003cb data-path-to-node=\"5\" data-index-in-node=\"0\"\u003eTarget Audience\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cul\u003e\n \t\u003cli data-path-to-node=\"5\"\u003eThe IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.\u003c\/li\u003e\n \t\u003cli data-path-to-node=\"5\"\u003eBest for hematologists, medical oncologists, nephrologists, and infectious disease specialists.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp data-path-to-node=\"6\"\u003e\u003cb data-path-to-node=\"6\" data-index-in-node=\"0\"\u003eTopics\u003c\/b\u003e\u003c\/p\u003e\n\n\u003cul data-path-to-node=\"7\"\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,0,0\"\u003eMultiple Myeloma: A Cure is on the Horizon\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,1,0\"\u003eDiagnostic Testing for Multiple Myeloma, Risk Stratification and Follow-up\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,2,0\"\u003eUpdate and Recommendations on Imaging Techniques in Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,3,0\"\u003eMRD Testing in Multiple Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,4,0\"\u003eNew Risk Stratification in Multiple Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,5,0\"\u003eLive Panel Discussion: Diagnosis and Follow Up of Patients\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,6,0\"\u003eManagement of Clinical Significance\/Smoldering Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,7,0\"\u003eManagement of Newly Diagnosed MM Transplant Eligible\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,8,0\"\u003eManagement of Newly Diagnosed MM Non-Transplant Eligible\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,9,0\"\u003eLive Panel Discussion: How to Manage SMM and NDMM\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,10,0\"\u003eThe Future of Multiple Myeloma\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,11,0\"\u003eOptimal Sequencing for RRMM Patients in Their 1st and 2nd Relapse\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,12,0\"\u003eNovel Treatments for MM Besides Cell Therapies and Bispecifics\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,13,0\"\u003eLive Panel Discussion: Sequencing of Therapies in RRMM\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,14,0\"\u003eCAR T Cells\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,15,0\"\u003eBispecific T Cell Engagers\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,16,0\"\u003eLive Panel Discussion: Incorporating Novel Immunotherapies in Practice\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,17,0\"\u003eBone Disease and Renal Failure\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,18,0\"\u003eInfection and Vaccinations\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,19,0\"\u003eLive Panel Discussion: Managing Myeloma Related Complications\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,20,0\"\u003eWaldenström’s Macroglobulinemia\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,21,0\"\u003eAL Amyloidosis\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,22,0\"\u003eLive Panel Discussion: Managing Other Dysproteinemias\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,23,0\"\u003eRelapse After T Cell Redirected Therapies\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,24,0\"\u003eExtramedullary Disease and Plasma Cell Leukemia\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,25,0\"\u003eIncorporating Frailty Into Treatment Algorithms for MM\u003c\/p\u003e\n\u003c\/li\u003e\n \t\u003cli\u003e\n\u003cp data-path-to-node=\"7,26,0\"\u003eLive Panel Discussion: Challenging Questions in MM\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43113249570914,"sku":"MED-AMB09591","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/International-Myeloma-Society-Educational-Workshop-2025.jpg?v=1783964501","url":"https:\/\/meducourse.com\/products\/international-myeloma-society-educational-workshop-2025","provider":"Meducourse","version":"1.0","type":"link"}